Get the Stockscreener App
10.21
0.20%
-0.02
After Hours:
10.21
Helix Acquisition Corp Iii stock is traded at $10.21, with a volume of 20,799.
It is down -0.20% in the last 24 hours and up +0.00% over the past month.
Helix Acquisition Corp III is a blank check company.
See More
Previous Close:
$10.23
Open:
$10.21
24h Volume:
20,799
Relative Volume:
1.90
Market Cap:
$219.49M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$10.21
$10.25
1-Week Range:
$10.20
$10.35
52-Week Range:
$10.20
$10.35
Helix Acquisition Corp Iii Stock (HLXC) Company Profile
Name
Helix Acquisition Corp Iii
Sector
Industry
Phone
-
Address
-
Compare HLXC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HLXC
Helix Acquisition Corp Iii
|
10.21 | 219.92M | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
9.44 | 2.75B | 3.13B | -174.20M | -111.20M | -0.6937 |
|
XXI
Twenty One Capital Inc
|
7.60 | 2.63B | 0 | 0 | 0 | 0.00 |
|
CCCX
Churchill Capital Corp X
|
13.50 | 804.69M | 0 | 0 | 0 | 0.00 |
|
DMII
Drugs Made In America Acquisition Ii Corp
|
9.97 | 653.13M | 0 | 0 | 0 | 0.00 |
|
CEPF
Cantor Equity Partners Iv Inc
|
10.47 | 597.79M | 0 | 0 | 0 | 0.00 |
Helix Acquisition Corp Iii Stock (HLXC) Latest News
With a Thin IPO Calendar, Hedge Funds Are Zeroing In on Biopharma - Institutional Investor
Will Helix Acquisition Corp. II stock continue dividend increasesRate Cut & AI Forecast Swing Trade Picks - mfd.ru
Helix Acquisition Corp. III raises $172.5 million in Nasdaq IPO By Investing.com - Investing.com Nigeria
Helix Acquisition Corp III closes $172.5 million IPO By Investing.com - Investing.com South Africa
Helix Acquisition Corp. III closes $172.5 million IPO By Investing.com - Investing.com Australia
Helix Acquisition Corp. III raises $172.5 million in Nasdaq IPO - Investing.com
Helix Acquisition Corp. III closes $172.5 million IPO - Investing.com India
Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares - The Manila Times
SL Green Realty Corp. Announces Date of 2026 Annual Meeting of Stockholders - The Manila Times
White & Case advises Helix Acquisition Corp. III on upsized US$150 million IPO - White & Case LLP
Biotech investor Cormorant secures $150M for another SPAC deal - BioPharma Dive
Helix Acquisition prices $150M initial public offering - MSN
Helix Acquisition III Raises $150 Million, Targets Healthcare Sector - Intellectia AI
Helix Acquisition Corp. III Prices Upsized $150 Mln IPO - Nasdaq
Helix Acquisition Corp. III Announces Pricing of Upsized $150 Million Initial Public Offering - The Manila Times
Helix Acquisition III launches $150M healthcare-focused SPAC IPO - Stock Titan
Day One was one of three parties interested in Mersana; Bihua Chen and Cormorant’s third SPAC - Endpoints News
HLXC IPO NewsCormorant's SPAC Helix Acquisition III files for a $125 million IPO, targeting healthcare - renaissancecapital.com
BBOT Debuts as a Publicly Traded Company Focused on - GlobeNewswire
BridgeBio Oncology Lands Massive $382M SPAC Deal as Top Investors Back Cancer Drug Pipeline - Stock Titan
BridgeBio Oncology's SPAC Merger Advances: SEC Clears Path for Novel Cancer Drug Development Platform - Stock Titan
Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal - BioSpace
Helix Acquisition Corp. II SEC 10-Q Report - TradingView
Swiss ADC Biotech Takes SPAC Track to NASDAQ - BioSpace
BridgeBio Oncology and Helix enter definitive merger agreement - Pharmaceutical Technology
BridgeBio spinout to go public in SPAC deal (HLXB:NASDAQ) - Seeking Alpha
Life Sciences Hedge Fund Perceptive Preps a New SPAC - Institutional Investor
Helix Acquisition Corp. II Closes of $184 Million IPO - citybiz
Helix Acquisition Corp. II Prices of Upsized $160 Million IPO - citybiz
Cormorant Launches Second SPAC Following MoonLake Deal with $100M IPO - BioSpace
MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody® Sonelokimab - Business Wire
Helix Acquisition Corp Iii Stock (HLXC) Financials Data
There is no financial data for Helix Acquisition Corp Iii (HLXC). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.64%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):